Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1748-717X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment ; volume:7 ; number:1 ; day:12 ; month:6 ; year:2012 ; pages:1-9 ; date:12.2012
Radiation oncology ; 7, Heft 1 (12.6.2012), 1-9, 12.2012
- Urheber
-
Lee, Dong Soo
- Beteiligte Personen und Organisationen
-
Kim, Yeon Sil
Cheon, Jae Seok
Song, Jin Ho
Son, Seok Hyun
Jang, Ji Sun
Kang, Young Nam
Kang, Jing Hyoung
Jung, So Lyoung
Yoo, Ie Ryung
Jang, Hong Seok
SpringerLink (Online service)
- DOI
-
10.1186/1748-717X-7-85
- URN
-
urn:nbn:de:1111-2016072616564
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lee, Dong Soo
- Kim, Yeon Sil
- Cheon, Jae Seok
- Song, Jin Ho
- Son, Seok Hyun
- Jang, Ji Sun
- Kang, Young Nam
- Kang, Jing Hyoung
- Jung, So Lyoung
- Yoo, Ie Ryung
- Jang, Hong Seok
- SpringerLink (Online service)
Ähnliche Objekte (12)
Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible
Hypofractionated Radiotherapy With Simultaneous-integrated Boost After Breast-conserving Surgery Compared to Standard Boost-applications Using Helical Tomotherapy With TomoEdge
Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer
Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity
Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial
Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?
PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol
Normal tissue toxicity after small field hypofractionated stereotactic body radiation
SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment
Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters
Comparative analysis of toxicity in patients with anal cancer undergoing definitive simultaneous integrated boost (SIB) or sequential integrated boost (SeqB) radiotherapy
Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible
Hypofractionated Radiotherapy With Simultaneous-integrated Boost After Breast-conserving Surgery Compared to Standard Boost-applications Using Helical Tomotherapy With TomoEdge
Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer
Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity
Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial
Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?
PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol
Normal tissue toxicity after small field hypofractionated stereotactic body radiation
SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment
Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters
Comparative analysis of toxicity in patients with anal cancer undergoing definitive simultaneous integrated boost (SIB) or sequential integrated boost (SeqB) radiotherapy
Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible
Hypofractionated Radiotherapy With Simultaneous-integrated Boost After Breast-conserving Surgery Compared to Standard Boost-applications Using Helical Tomotherapy With TomoEdge
Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer
Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity
Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial
Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?
PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol
Normal tissue toxicity after small field hypofractionated stereotactic body radiation
SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment
Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters